Abstract
Gender medicine is the topic of this issue of The Biochemist. In 2014, Francis Collins, Director of the National Institutes of Health (NIH), and Janine Clayton, Director of the Office of Research on Women's Health (ORWH) at NIH, announced that NIH would begin requiring all preclinical grant proposals to address sex as a biological variable1. The ORWH was set up in 1990 with the specific mandate to promote the inclusion of women and minority individuals in all clinical trials going forward2. Similar guidelines are imposed by the European Commission and the Canadian Institutes of Health Research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
